Table 3.

Treatment-emergent AEs in phase II

Patients with event, n (%)Follicular lymphoma (n = 16)Mantle cell lymphoma (n = 14)Total (N = 30)
Any-grade AEs occurring in >20% of patients
Nausea12 (75.0)7 (50.0)19 (63.3)
Fatigue10 (62.5)8 (57.1)18 (60.0)
Diarrhea8 (50.0)7 (50.0)15 (50.0)
Thrombocytopenia10 (62.5)4 (28.6)14 (46.7)
Cough6 (37.5)7 (50.0)13 (43.3)
Vomiting8 (50.0)3 (21.4)11 (36.7)
Constipation7 (43.8)3 (21.4)10 (33.3)
Decreased appetite5 (31.3)3 (21.4)8 (26.7)
Headache5 (31.3)3 (21.4)8 (26.7)
Peripheral edema3 (18.8)5 (35.7)8 (26.7)
Anemia4 (25.0)4 (28.6)8 (26.7)
Neutropenia4 (25.0)3 (21.4)7 (23.3)
Dysgeusia4 (25.0)3 (21.4)7 (23.3)
Sinusitis3 (18.8)4 (28.6)7 (23.3)
Insomnia5 (31.3)1 (7.1)6 (20.0)
Chills1 (6.3)5 (35.7)6 (20.0)
Grade 3 or 4 AEs occurring in more than one patient
Thrombocytopenia3 (18.8)3 (21.4)6 (20.0)
Fatigue2 (12.5)3 (21.4)5 (16.7)
Neutropenia2 (12.5)2 (14.3)4 (13.3)
Hyperglycemia0 (0)2 (14.3)2 (6.7)
Performance status decrease1 (6.3)1 (7.1)2 (6.7)
Arthralgia1 (6.3)1 (7.1)2 (6.7)

NOTE: Treatment-emergent AEs are events with onset dates on or after the start of treatment and up to 30 days after the last dose date, or continuing AEs diagnosed before the start of treatment and getting worse in grade or relationship to treatment after the start of treatment. Counts and percentages are of patients, not events.